2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersVaccines as Immunotherapies for Substance Use Disorders
Kosten T. Vaccines as Immunotherapies for Substance Use Disorders. American Journal Of Psychiatry 2024, 181: 362-371. PMID: 38706331, DOI: 10.1176/appi.ajp.20230828.Peer-Reviewed Original ResearchConceptsSubstance use disordersHuman clinical trials of vaccinesPreclinical vaccine studiesClinical trials of vaccinesVaccine clinical trialsHuman clinical trialsTrials of vaccinesVaccine immunotherapyIllicit fentanyl useOpioid pharmacotherapyEffective therapySubstance use disorder treatmentFentanyl useClinical trialsVaccine studiesAnimal modelsAnimal studiesUse disorderVaccine technologyLethal overdoseImmunotherapyVaccineLimited treatment accessFentanyl overdoseTreatment accessPrediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models
Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T, Ryan N, Kirisci L, Wang L. Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models. Drug And Alcohol Dependence 2024, 255: 111066. PMID: 38217979, PMCID: PMC10853953, DOI: 10.1016/j.drugalcdep.2023.111066.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderAlcohol use disorderComorbid post-traumatic stress disorderStress disorderUse disorderCognitive behavioral therapyElectronic medical recordsBehavioral therapyMental disordersNeighborhood-level social determinants of healthNeighborhood-level social determinantsSocial determinants of healthArea under the receiver operating curveDeterminants of healthVeteran dataMedical recordsDisordersPsychotherapyPrediction of adverse eventsVeteran statusPatient's increased riskHigh-risk populationAnalyzed electronic medical recordsUniversity of Pittsburgh Medical CenterAdverse events
2023
MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations
Grimm S, Mendez E, Stertz L, Meyer T, Fries G, Gandhi T, Kanchi R, Selvaraj S, Teixeira A, Kosten T, Gunaratne P, Coarfa C, Walss-Bass C. MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations. Frontiers In Psychiatry 2023, 13: 1025346. PMID: 36713930, PMCID: PMC9878702, DOI: 10.3389/fpsyt.2022.1025346.Peer-Reviewed Original ResearchOpioid use disorderUse disorderPostmortem brainsDorsolateral prefrontal cortexResponses to opioid drugsGenotype-Tissue ExpressionImmune system alterationsPrefrontal cortexNeurobiological alterationsBlood-brain barrierMiRNA targetsEpigenetic regulation of gene functionOpioid drugsRegulation of gene functionOpioid abuseTGF-betaGene signatureInflammatory pathwaysPotential functional impactSystem alterationsImmune systemBrain transcriptomeEndothelial cellsNeurovascular alterationsPostmortem samples